AU2021224585A1 - Group A strep immunogenic compositions with polysaccharide-protein conjugates - Google Patents

Group A strep immunogenic compositions with polysaccharide-protein conjugates Download PDF

Info

Publication number
AU2021224585A1
AU2021224585A1 AU2021224585A AU2021224585A AU2021224585A1 AU 2021224585 A1 AU2021224585 A1 AU 2021224585A1 AU 2021224585 A AU2021224585 A AU 2021224585A AU 2021224585 A AU2021224585 A AU 2021224585A AU 2021224585 A1 AU2021224585 A1 AU 2021224585A1
Authority
AU
Australia
Prior art keywords
seq
polypeptide
immunogenic composition
gas
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021224585A
Other languages
English (en)
Inventor
Peter T. Davey
Jeffery C. FAIRMAN
Neeraj Kapoor
Angie A. Sedra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxcyte Inc
Original Assignee
Vaxcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte Inc filed Critical Vaxcyte Inc
Publication of AU2021224585A1 publication Critical patent/AU2021224585A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/2111—C5a peptidase (3.4.21.110)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2021224585A 2020-02-18 2021-02-17 Group A strep immunogenic compositions with polysaccharide-protein conjugates Pending AU2021224585A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062977886P 2020-02-18 2020-02-18
US62/977,886 2020-02-18
US202063013924P 2020-04-22 2020-04-22
US63/013,924 2020-04-22
US202063090069P 2020-10-09 2020-10-09
US63/090,069 2020-10-09
US202063123293P 2020-12-09 2020-12-09
US63/123,293 2020-12-09
PCT/US2021/018402 WO2021167996A1 (en) 2020-02-18 2021-02-17 Group a strep immunogenic compositions with polysaccharide-protein conjugates

Publications (1)

Publication Number Publication Date
AU2021224585A1 true AU2021224585A1 (en) 2022-10-13

Family

ID=74860575

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021224585A Pending AU2021224585A1 (en) 2020-02-18 2021-02-17 Group A strep immunogenic compositions with polysaccharide-protein conjugates

Country Status (13)

Country Link
US (1) US20230293658A1 (cg-RX-API-DMAC7.html)
EP (1) EP4106807A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023514332A (cg-RX-API-DMAC7.html)
KR (1) KR20220143107A (cg-RX-API-DMAC7.html)
CN (1) CN115175697A (cg-RX-API-DMAC7.html)
AU (1) AU2021224585A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016268A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168201A1 (cg-RX-API-DMAC7.html)
IL (1) IL295702A (cg-RX-API-DMAC7.html)
MX (1) MX2022010129A (cg-RX-API-DMAC7.html)
PH (1) PH12022552118A1 (cg-RX-API-DMAC7.html)
TW (1) TW202136285A (cg-RX-API-DMAC7.html)
WO (1) WO2021167996A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538365A (ja) 2020-08-19 2023-09-07 バックスサイト・インコーポレイテッド 担体－タンパク質多糖結合方法
JP2024506713A (ja) * 2021-02-17 2024-02-14 バックスサイト・インコーポレイテッド 多糖およびそのポリペプチドコンジュゲートの精製方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
NZ586430A (en) * 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
WO2013020090A2 (en) 2011-08-04 2013-02-07 The Regents Of The University Of California STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
AU2013320313B2 (en) * 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
IL267709B2 (en) * 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids

Also Published As

Publication number Publication date
MX2022010129A (es) 2022-09-05
TW202136285A (zh) 2021-10-01
CN115175697A (zh) 2022-10-11
IL295702A (en) 2022-10-01
PH12022552118A1 (en) 2024-01-29
EP4106807A1 (en) 2022-12-28
WO2021167996A1 (en) 2021-08-26
JP2023514332A (ja) 2023-04-05
US20230293658A1 (en) 2023-09-21
KR20220143107A (ko) 2022-10-24
BR112022016268A2 (pt) 2022-10-11
CA3168201A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
EP1858920B1 (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
RU2563808C2 (ru) Модифицированный капсулярный сахарид, способ его получения и применение
CN101031584B (zh) 脑膜炎球菌蛋白nmb1870的结构域和表位
EP2298795A1 (en) Immunogens from uropathogenic escherichia coli
WO2008020330A9 (en) Immunogens from uropathogenic escherichia coli
EP3077410B1 (en) Proline-rich peptides protective against s. pneumoniae
CN102917730A (zh) 修饰的脑膜炎球菌fHBP多肽
MX2008016280A (es) Polipeptidos a partir de neisseria meningitidis.
EP0399001A1 (en) T CELL EPITOPES AS CARRIER MOLECULES FOR CONJUGATED VACCINES.
CN112566657A (zh) 修饰的脑膜炎球菌fHbp多肽
AU2022221621A9 (en) Purification processes for polysaccharides and polypeptide conjugates thereof
US20230293658A1 (en) Group a strep immunogenic compositions with polysaccharide-protein conjugates
CN102770443A (zh) 脱毒大肠杆菌免疫原
US20150273042A1 (en) Pilus proteins and compositions
KR100366482B1 (ko) 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법
JP2018522978A (ja) 免疫原性組成物
CN114025789A (zh) 侵入质粒抗原b的经优化的无细胞合成和有关的组合物及使用方法
EP4190799A1 (en) Amino acid sequence derived from sars-cov-2 and use thereof
HK40098012A (en) A bacterial polysaccharide protein conjugate and use thereof
HK1160659A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EA043165B1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp